Daniel J. O'Connor - 05 Jul 2023 Form 4 Insider Report for Ambrx Biopharma Inc.

Reporting relationship: President and CEO, Director
Issuer ticker: N/A
Reported as of: 05 Jul 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jul 2023, 16:06:29 UTC
Prior SEC filing: 28 Apr 2023
Next SEC filing: 31 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/ Sonja Nelson, attorney in fact for Daniel O'Connor

Key filing fact

Daniel J. O'Connor filed Form 4 for Ambrx Biopharma Inc. on 07 Jul 2023.

Key facts

This page summarizes Daniel J. O'Connor's Form 4 filing for Ambrx Biopharma Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Jul 2023, 16:06.

Change

Previous filing in this sequence was filed on 28 Apr 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMAM transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,216,500
Change %
Price: $0.000000
Shares after: 1,216,500
Date: 05 Jul 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 1,216,500
Exercise price: $2.38
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

Footnote F2

1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date.

Footnote F3

The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer.